Krystal Biotech shares reached a new 52-week high of $382.54 during Wednesday's trading session. The stock maintains significant upward momentum following gains over the past month.
The company reported quarterly earnings of $1.83 per share. This figure surpassed the consensus analyst estimate of $1.45. Revenue reached $116.36 million, which also exceeded market expectations.
Wall Street sentiment remains positive with a majority of analysts rating the stock as a Buy. Institutional ownership in the company currently exceeds 86%.